Sowell Financial Services LLC Invests $294,000 in Celgene Co. (CELG)
Sowell Financial Services LLC bought a new stake in Celgene Co. (NASDAQ:CELG) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 2,441 shares of the biopharmaceutical company’s stock, valued at approximately $294,000.
A number of other large investors have also added to or reduced their stakes in CELG. First Financial Corp IN boosted its stake in Celgene by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 228 shares during the last quarter. Barnett & Company Inc. increased its position in shares of Celgene by 18.3% in the third quarter. Barnett & Company Inc. now owns 1,130 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 175 shares during the period. Cornerstone Advisors Inc. increased its position in shares of Celgene by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 884 shares during the period. Harvest Fund Management Co. Ltd bought a new position in shares of Celgene during the fourth quarter valued at about $146,000. Finally, Bank Hapoalim BM bought a new position in shares of Celgene during the third quarter valued at about $147,000. Hedge funds and other institutional investors own 77.68% of the company’s stock.
Celgene Co. (NASDAQ:CELG) traded down 0.823% during midday trading on Friday, reaching $122.255. 2,379,530 shares of the company’s stock traded hands. Celgene Co. has a 52-week low of $94.42 and a 52-week high of $127.64. The firm has a market cap of $95.11 billion, a PE ratio of 49.098 and a beta of 1.74. The firm’s 50-day moving average is $124.35 and its 200 day moving average is $116.33.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.59 by $0.02. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $3.03 billion. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The firm’s revenue was up 16.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 EPS. Equities research analysts expect that Celgene Co. will post $7.23 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on CELG shares. Cann reiterated a “buy” rating on shares of Celgene in a report on Thursday, January 26th. Cantor Fitzgerald reiterated a “buy” rating and set a $159.00 price target on shares of Celgene in a report on Friday, January 6th. Cowen and Company reiterated an “outperform” rating and set a $150.00 price target on shares of Celgene in a report on Thursday, January 12th. Mizuho set a $130.00 price objective on Celgene and gave the company a “buy” rating in a report on Sunday, February 19th. Finally, Vetr downgraded Celgene from a “strong-buy” rating to a “buy” rating and set a $131.49 price objective for the company. in a report on Tuesday, January 17th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $139.46.
In other Celgene news, Director Gilla Kaplan sold 14,033 shares of the firm’s stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the transaction, the director now owns 73,109 shares of the company’s stock, valued at approximately $9,053,087.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rupert Vessey sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total transaction of $497,680.00. Following the transaction, the insider now directly owns 778 shares in the company, valued at approximately $96,798.76. The disclosure for this sale can be found here. Company insiders own 0.97% of the company’s stock.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related stocks with our FREE daily email newsletter.